Minnesota Journal of Law, Science and Technology, Vol. 27: Iss. 2
In January 2025, the U.S. Federal Trade Commission (FTC) reported that a new form of “possible compensation” from brand drug manufacturers to generic (or biosimilar) manufacturers, specifically “quantity restrictions,” have become “increasingly prevalent” in pharmaceutical patent settlement agreements filed with...